How is retatrutide injected?
Retatrutide is a once-weekly subcutaneous injection, like tirzepatide. In trials it's given with a pen or prefilled syringe into the abdomen, thigh, or upper arm.
Updated May 26, 2026 · 3 min read
Retatrutide is administered as a once-weekly subcutaneous injection — the same delivery method as tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy). In the phase 2 and phase 3 TRIUMPH trials, participants received it as a prefilled autoinjector pen or manual injection. When and if it receives FDA approval, the delivery device will be confirmed by Eli Lilly, but a subcutaneous weekly pen is the expected form.
What subcutaneous means in practice
Subcutaneous means the injection goes into the fat layer just beneath the skin — not into muscle. Approved sites are the same three used for semaglutide and tirzepatide:
- Abdomen — at least 2 inches from the navel, alternating sides
- Thigh — outer upper thigh
- Upper arm — outer area (usually done by a helper or injecting into dominant arm)
The needle is short (typically 4–8 mm) and thin (29–32 gauge). Most people find subcutaneous injections significantly less painful than they expected. The common description is a slight pinch.
You rotate injection sites from week to week. Injecting into the same spot repeatedly causes lipohypertrophy — a thickening of fatty tissue that reduces drug absorption and creates lumps under the skin.
Pen vs. vial: what to expect at launch
The two most likely delivery formats for retatrutide at launch, based on tirzepatide's commercial rollout:
Autoinjector pen (like Zepbound): Pre-loaded with a single dose. You press the pen against skin, click to inject, and remove. No dose measurement required. This is the standard commercial format and the most likely option for brand-name retatrutide.
Manual syringe from vial (compounded): Compounded retatrutide — which exists in a gray market now for research purposes and may eventually exist legally under different circumstances — comes as a lyophilized powder requiring reconstitution with bacteriostatic water. You draw up the dose with a 1 mL insulin syringe. This requires more steps and introduces room for dosing error, but it's the same technique millions of people use for compounded semaglutide.
One important note: there is currently no FDA-approved retatrutide product. Any retatrutide injection being used now is either from a trial or from research-grade sourcing outside the prescription system. The information above about delivery format applies to what's expected at commercial launch based on Lilly's existing products.
How does the trial injection protocol work?
In the TRIUMPH phase 3 trials, participants receive retatrutide at escalating doses — starting at a lower amount and stepping up over several weeks. The titration exists for the same reason as tirzepatide's: GI side effects (nausea, vomiting, diarrhea) are dose-dependent, and starting low lets the gut adapt before reaching therapeutic levels.
The specific TRIUMPH titration schedule has not been fully published in public data as of mid-2026. Based on phase 2 protocol, participants moved through several dose levels (0.5 mg, 1 mg, 2 mg, 4 mg, 8 mg, 12 mg) with 4-week intervals between steps. The commercial titration schedule, if approved, will likely simplify this.
Weekly shot vs. other timing options
There are no approved oral or extended-release non-weekly versions of retatrutide in development as of mid-2026. Lilly has invested heavily in the weekly subcutaneous format across its GLP-1 portfolio. Unlike Novo Nordisk (which has Rybelsus as an oral semaglutide), Lilly hasn't announced an oral retatrutide program publicly.
The practical implication: if you're needle-averse, retatrutide is currently expected to be injection-only at launch.